[an error occurred while processing this directive] | [an error occurred while processing this directive]
Clinical effects of concurrent radiochemotherapy followed by radical surgery and radical radiotherapy with concurrent chemotherapy:a comparative study of 243 patients with FIGO stage ⅡB cervical cancer
WANG Ning, WEI Li-chun, SHI Mei, LI Wei-wei, Hu Jing, LIU Juan-yue, LI Jian-ping, ZHOU Yong-chun, ZHANG Ying
Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi′an 710032, China
Abstract Objective To compare concurrent radiochemotherapy (CRCT) followed by radical surgery and radical radiotherapy (RT) with concurrent weekly cisplatin in terms of survival rates and long-term toxicities in patients with FIGO stage ⅡB cervical cancer. Methods A retrospective analysis was performed on 243 patients with FIGO stage ⅡB cervical cancer who were admitted to our hospital from November 2004 to November 2011. Of the 243 patients, 121 patients received CRCT followed by radical surgery (group 1), and 122 received radical RT with concurrent chemotherapy (weekly cisplatin, 40 mg/m2)(group 2). The Kaplan-Meier method wasused to calculate survival rates, and the log-rank test wasused for survival difference analysis;the Cox model was used for multivariate prognostic analysis.ResultsThe follow-up rate was 100% in groups 1 and 2. 34 and 33 patients were followed up for at least 3 years in groups 1 and 2. The 3-year progression-free survival (PFS) rates, overall survival (OS) rates, and local control rates for groups 1 and 2 were 91.5% vs 82.0%(P=0.013), 95.5% vs 89.2%(P=0.085), and 96.7% vs 93.4%(P=0.375), respectively. In group 1, the patients with a tumor diameter of ≥6 cm and an age of ≤35 years had a significantly lower 3-year PFS rate than those with a tumor diameter of<6 cm and an age of>35 years (68.2% vs 93.8%, P=0.004;74.1% vs 93.2%, P=0.037). In group 2, the patients with non-squamous cell carcinoma and a tumor diameter of ≥6 cm had a significantly lower 3-year PFS rate than those with squamous cell carcinoma and a tumor diameter of<6 cm (50.0% vs 83.0%, P=0.013;25.0% vs 86.0%, P=0.002). In groups 1 and 2, the patients with a tumor diameter of ≥6 cm had a significantly lower 3-year OS rate than those with a tumor diameter of<6 cm (78.8% vs 97.0%, P=0.033;46.9% vs 92.6%, P=0.007). Leg edema occurred more frequently in group 1 than in group 2(33.1% vs 8.2%, P=0.000), while radiation enteritis more frequently in group 2 than in group 1(31.2% vs 5.0%, P=0.000). Conclusions CRCT followed by radical surgery may lead to better PFS than radical RT with weekly cisplatin in patients with FIGO stage ⅡB cervical cancer. Tumor diameter is the common prognostic factor for PFS in patients who receive the two treatments.
Corresponding Authors:
SHI Mei, Email:mshi82@fmmu.edu.cn.
E-mail: mshi82@fmmu.edu.cn
Cite this article:
WANG Ning,WEI Li-chun,SHI Mei et al. Clinical effects of concurrent radiochemotherapy followed by radical surgery and radical radiotherapy with concurrent chemotherapy:a comparative study of 243 patients with FIGO stage ⅡB cervical cancer[J]. Chinese Journal of Radiation Oncology, 2013, 22(4): 274-277.
WANG Ning,WEI Li-chun,SHI Mei et al. Clinical effects of concurrent radiochemotherapy followed by radical surgery and radical radiotherapy with concurrent chemotherapy:a comparative study of 243 patients with FIGO stage ⅡB cervical cancer[J]. Chinese Journal of Radiation Oncology, 2013, 22(4): 274-277.
[1] Thomas G. Are we making progress in curing advanced cervical cancer? J Clin Oncol,2011,28:1654-1656. [2] Song S, Song C, Kim HJ, et al. 20 year experience of postoperative radiotherapy in ⅠB-ⅡA cervical cancer patients with intermediate risk factors:Impact of treatment period and concurrent chemotherapy. Gynecol Oncol,2012,124:63-67. [3] Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin,2012,62:10-29. [4] Houvenaeghel G, Lelievre L, Buttarelli M, et al. Contribution of surgery in patients with bulky residual disease after chemoradiation for advanced cervical carcinoma. Eur J Surg Oncol,2007,33:498-503. [5] Fanfani F, Fagotti A, Ferrandina G, et al. Neoadjuvant chemoradiation followed by radical hysterectomy in FIGO Stage ⅢB cervical cancer:feasibility, complications, and clinical outcome. Int J Gynecol Cancer,2009,19:1119-1124. [6] Ferrandina G, Legge F, Fagotti A, et al. Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer:safety, outcome, and prognostic measures. Gynecol Oncol,2007,107(1 Suppl 1):S127-132. [7] Macchia G, Ferrandina G, Deodato F, et al. Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix:results of a phase Ⅰ study (LARA-CC-1). Gynecol Oncol,2010,118:128-133. [8] Yin M, Zhao F, Lou G, et al. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer. Int J Gynecol Cancer,2011,21:92-99. [9] Classe JM, Rauch P, Rodier JF, et al. Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer:morbidity and outcome:results of a multicenter study of the GCCLCC (Group des Chirurgiens de Centre de Lutte contre le Cancer). Gynecol Oncol,2006,102:523-529. [10] Chassagne D, Sismondi P, Horiot JC, et al. A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol,1993,26:195-202. [11] Yamashita H, Nakagawaa K, Tagoa M, et al. Comparison between conventional surgery and radiotherapy for FIGO stage Ⅰ－Ⅱ cervical carcinoma:a retrospective Japanese study. Gynecol Oncol,2005,97:834-839. [12] Mabuchi S, Morishige K, Isohashi F, et al. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors. Gynecol Oncol,2009,115:482-487. [13] Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ⅰb-Ⅱa cervical cancer. Lancet,1997,350:535-540. [14] Morley GW, Seski JC. Radical pelvic surgery versus radiation therapy for stage Ⅰ carcinoma of the cervix (exclusive of microinvasion). Am J Obstet Gynecol,1976,126:785-798. [15] Perez CA, Camel HM, Kao MS, et al. Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage ⅠB and ⅡA carcinoma of the uterine cervix:final report. Gynecol Oncol,1987,27:129-140. [16] Morice P, Rouanet P, Rey A, et al. Results of the GYNECO 02 study, an FNCLCC phase Ⅲ trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage ⅠB2 or Ⅱ cervical cancer. Oncologist,2012,17:64-71. [17] Motton S, Houvenaeghel G, Delannes M, et al. Results of surgery after concurrent chemoradiotherapy in advanced cervical cancer:comparison of extended hysterectomy and extrafascial hysterectomy. Int J Gynecol Cancer,2010,20:268-275. [18] Lèguevaque P, Motton S, Delannes M, et al. Completion surgery or not after concurrent chemoradiotherapy for locally advanced cervical cancer? Eur J Obstet Gynecol Reprod Biol,2011,155:188-192. [19] Gadducci A, Fabrini MG, Perrone F, et al. Pattern of failures and clinical outcome of patients with locally advanced cervical cancer treated with a tailored integrated therapeutic approach. Anticancer Res,2010,30:3731-3735. [20] Houvenaeghel G, Martino M, Bladou F, et al. Value of surgery in the treatment of advanced cervical cancers. Ann Chir,1998,52:425-433. [21] Hirakawa M, Nagai Y, Toita T, et al. High-risk group for locoregional recurrence in patients with stage ⅠB-ⅡB squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy. Anticancer Res,2011,31:1437-1441. [22] International federation of gynecology and obstetrics (FIGO).26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet,2006,95(Suppl 1):S43-103. [23] Aoki Y, Sato T, Watanabe M, et al. Neoadjuvant chemotherapy using low-dose consecutive intraarterial infusion of cisplatin combined with 5 FU for locally advanced cervical adenocarcinoma. Gynecol Oncol,2001,83:496-499.
2013, Vol. 22 
